Latent Earns a 94.5 in the 2026 KLAS Emerging Company Spotlight

KLAS scored Latent Health 94.5 overall, with A+ ratings for likelihood to recommend, partnership, and would buy again, in the first KLAS Spotlight report on enterprise pharmacy intelligence.

GLP-1 Bridge is Here. How Latent Helps

Medicare's GLP-1 Bridge could make millions more people eligible for medicines that used to run $1,000+/month, for about $50. What it means for pharmacy teams, and how we're helping our partners meet the wave.

Pushing the Pareto Frontier for Clinical Deidentification

CIPHER is Latent's 1.5B-parameter de-identification model: frontier-level recall of 97.9% on PHI redaction at about 1/1000th the inference cost of frontier LLMs.

Latent Raises $80M to Close the Gap Between Diagnosis and Treatment

Adaptive LLMs for Medical Question Answering via Evolution